| abstract |
The present invention provides 4- isopropylphenylglucitol compounds that have no tendency to accumulate in the body and that inhibit the activity of SGLT1 to suppress postprandial hyperglycemia (or impaired glucose tolerance) by suppressing glucose uptake in the intestine thin, whereby the compounds, for example, can suppress the onset of diabetes and the metabolic syndrome or can treat these diseases.A 4-isopropylphenylglucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: [Chem 1] wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group or amino groups, etc. and R4 represents a hydrogen atom, etc. |